Genetic test regulation problems loom on the horizon?
This article was originally published in Clinica
Problems could lie ahead for the US in its efforts to regulate genetic tests, according to a highly-respected Washington attorney. Jonathan Kahan, an attorney in the law firm of Hogan & Hartson, told last week's annual meeting of the Association of Medical Diagnostic Manufacturers that the FDA's current regulatory approach is "unworkable."
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.